Mitochondrial Peptides in Canada: A Research Guide to SS-31, MOTS-c, Humanin, and NAD+

Why mitochondrial peptides need a dedicated Canadian guide#

Mitochondria are easy to over-romanticise. In supplier copy and longevity forums, anything connected to ATP, oxidative stress, or cellular energy can be compressed into the same promise: better mitochondria, healthier cells, slower aging. That language is commercially convenient, but it is scientifically imprecise. Mitochondrial research spans membrane architecture, respiratory-chain flux, mitochondrial DNA, mitophagy, peptide signalling, redox state, calcium handling, apoptosis, inflammatory signalling, and tissue-specific energy demand. A compound that touches one of those systems is not automatically interchangeable with every other compound in the category.

Northern Compound already has dedicated guides to SS-31, MOTS-c, Humanin, and NAD+. What was missing was a map for researchers who are comparing the mitochondrial cluster itself. A Canadian lab might see all four names in anti-aging or metabolic catalogues and ask a reasonable question: which material best matches a study on mitochondrial dysfunction, and what documentation is needed before a vial label can be trusted?

This article fills that decision layer. It does not rank compounds by personal benefit. It does not provide dosing instructions, self-administration guidance, compounding recipes, or treatment recommendations. It asks a narrower research question: how do mitochondrial peptides and related compounds differ mechanistically, how mature is the evidence for each, and what quality-control standards should Canadian researchers apply when sourcing research-use-only material?

The public archive category is anti-aging because mitochondrial dysfunction is a central geroscience theme and because SS-31, Humanin, NAD+, and mitochondrial-derived peptides are commonly discussed in longevity research. The guide also crosses into weight-management through MOTS-c and into disease models through SS-31, but the search intent is broader than metabolism alone: readers are asking how mitochondrial-targeted materials fit into cellular ageing and bioenergetics research.

The short answer: match the compound to the mitochondrial layer#

The most important distinction is level of action. SS-31 is a mitochondria-targeted tetrapeptide that associates with the inner mitochondrial membrane and cardiolipin. MOTS-c is a mitochondrial open reading frame-derived peptide with reported effects on metabolic stress signalling, AMPK pathways, and nuclear transcriptional responses. Humanin is another mitochondrial-derived peptide, usually discussed around cytoprotection, apoptosis modulation, insulin sensitivity, and neurodegeneration models. NAD+ is a redox cofactor, not a peptide, but it is central to mitochondrial metabolism because the NAD+/NADH ratio influences dehydrogenase reactions, sirtuin activity, PARP activity, and cellular stress responses.

A study on cardiolipin peroxidation and cristae architecture should not start with MOTS-c simply because both labels mention mitochondria. A study on metabolic adaptation to energy stress should not treat SS-31 as an exercise-mimetic peptide unless the endpoint is specifically mitochondrial respiration or membrane organisation. A study on NAD+ salvage cannot infer Humanin biology from a change in NAD+/NADH ratio. Each compound can be valuable, but only when the hypothesis is specific enough to match the mechanism.

SS-31: mitochondria-targeted membrane pharmacology#

SS-31, also known as elamipretide, is the most literal mitochondria-targeted peptide in this guide. It is a short cationic aromatic tetrapeptide commonly written as D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2. Its unusual amino-acid composition matters: the D-arginine, dimethyltyrosine, cationic charge, and aromatic surface contribute to the peptide's affinity for mitochondrial membranes. Unlike some mitochondria-targeting small molecules, SS-31 does not depend on a triphenylphosphonium motif. Its research identity is tied to cardiolipin, the signature phospholipid of the inner mitochondrial membrane.

Cardiolipin is not just a structural lipid. It helps organise respiratory-chain complexes, stabilises cristae curvature, supports cytochrome c function, and participates in apoptotic signalling when oxidised or displaced. Reviews of SS-31 describe it as a peptide that can associate with cardiolipin, alter mitochondrial membrane electrostatics, reduce pathological reactive oxygen species, and improve aspects of oxidative phosphorylation in several disease models (Sabbah et al., 2025). That makes SS-31 a strong candidate for research questions where mitochondrial membrane organisation is central.

The evidence is more mature than many peptide categories, but it is still easy to overstate. In 2025, the U.S. FDA granted accelerated approval to elamipretide for Barth syndrome, a rare cardiolipin-remodelling disorder. That regulatory milestone is meaningful because it links the cardiolipin mechanism to a human disease context. It does not make research vials equivalent to an approved drug product, does not establish a general anti-aging indication, and does not determine Canadian therapeutic status.

The most responsible SS-31 research designs measure mitochondrial endpoints directly. Oxygen-consumption rate, respiratory-control ratio, membrane potential, ATP output, cardiolipin species, cristae morphology, cytochrome c behaviour, and mitochondrial ROS are all closer to the mechanism than broad claims about vitality or ageing. Functional endpoints can be added, but they should not replace the mitochondrial measurements. If a study shows behavioural or tissue-level changes without mitochondrial readouts, the causal link remains speculative.

For Canadian sourcing, SS-31 research material should be evaluated with more than a generic purity number. A useful COA should identify the full sequence, including D-Arg and dimethyltyrosine, confirm expected mass by mass spectrometry, report HPLC purity, match the vial lot, identify the counter-ion when relevant, and specify storage conditions. A vendor that cannot distinguish SS-31 from an ordinary tetrapeptide is not documenting the chemistry that makes the molecule interesting.

MOTS-c: mitochondrial-derived peptide or metabolic signalling tool?#

MOTS-c is often placed in the mitochondrial peptide category because it is encoded by a short open reading frame in mitochondrial 12S rRNA. That origin is scientifically important, but it can mislead readers into thinking MOTS-c works by physically repairing mitochondria. The literature is better described as mitochondrial-derived signalling. MOTS-c appears to communicate cellular energy stress to nuclear transcriptional programmes and metabolic pathways, with reported involvement of AMPK and related stress-response systems.

The original 2015 Cell Metabolism paper described MOTS-c as a mitochondrial-derived peptide that regulated metabolic homeostasis and influenced insulin sensitivity in animal models (Lee et al., 2015). Subsequent reviews have framed mitochondrial-derived peptides, including MOTS-c and Humanin, as part of a broader mitokine-like communication system linking mitochondrial status to whole-cell and tissue responses (Kim et al., 2018). This is a different research lane from SS-31. MOTS-c is not primarily a cardiolipin stabiliser. It is a signal.

That distinction changes endpoint selection. MOTS-c studies should pay close attention to metabolic stress, glucose handling, AMPK phosphorylation, gene expression, exercise-related adaptation, mitochondrial biogenesis markers, inflammatory tone, and tissue-specific metabolic phenotypes. Measuring oxygen consumption can still be useful, but respiration should not be the only endpoint unless the study is specifically testing whether MOTS-c changes mitochondrial function downstream of signalling.

MOTS-c also sits at the boundary between weight-management and anti-aging search intent. Northern Compound's dedicated MOTS-c Canada guide covers the metabolic literature in more detail. This mitochondrial guide frames MOTS-c in the anti-aging archive because mitochondrial-derived peptide signalling is often discussed in relation to age-associated metabolic decline, sarcopenia, insulin resistance, and cellular stress resilience. That does not justify therapeutic claims. It means researchers should be explicit about whether they are studying metabolism, ageing biology, exercise adaptation, or a specific disease model.

For MOTS-c research material, supplier documentation should confirm sequence identity, expected mass, HPLC purity, lot number, fill amount, storage conditions, and testing date. Because MOTS-c is longer and more complex than SS-31, truncation products and deamidation should be considered in stability review. The COA should be lot-matched and method-specific; a marketing page that says "99% pure" without chromatogram context is not enough for serious mitochondrial research.

Humanin: important science, unavailable product context#

Humanin is one of the most scientifically interesting mitochondrial-derived peptides, but it requires especially careful editorial handling. Humanin was first described in the context of neuroprotective research and is frequently discussed around apoptosis-related pathways, amyloid toxicity models, metabolic stress, insulin sensitivity, and age-associated cellular vulnerability. Reviews of mitochondrial-derived peptides describe Humanin as part of a stress-response network rather than a simple energy booster (Muzumdar et al., 2009; Kim et al., 2018).

Humanin should not be treated as a live Lynx product in this article. The Humanin product slug is confirmed unavailable in the Northern Compound workflow, so this guide does not use ProductLink for it and does not describe it as currently purchasable through Lynx. That is not a scientific judgement about Humanin; it is a link-integrity and reader-safety decision. A sourcing article should never send readers to a dead product page or imply availability that the store cannot support.

Mechanistically, Humanin is not SS-31. It does not concentrate at cardiolipin as a membrane-active tetrapeptide. It is usually framed as a secreted or intracellular peptide signal that may interact with receptors and apoptosis-associated proteins. That means Humanin research endpoints often involve cell survival, stress resistance, inflammatory markers, insulin signalling, and neurodegeneration-related assays rather than direct cardiolipin measurement.

The temptation in longevity writing is to collapse Humanin and MOTS-c into a single "mitochondrial-derived peptide" bucket. The bucket is useful, but not sufficient. MOTS-c is often discussed in metabolic adaptation and AMPK-linked pathways. Humanin is often discussed in cytoprotection and apoptosis-linked pathways. A study that substitutes one for the other without changing endpoints is poorly designed.

Canadian researchers who encounter Humanin from any supplier should apply the same documentation standard used elsewhere: sequence identity, HPLC purity, mass spectrometry, lot matching, fill amount, storage conditions, and clear research-use-only language. They should also verify current legality, import requirements, institutional approval, and whether the supplier is making medical claims. Humanin's scientific interest does not remove the need for conservative sourcing.

NAD+: the non-peptide comparator that belongs in the discussion#

NAD+ is not a peptide. It is a nicotinamide adenine dinucleotide cofactor involved in redox reactions and cellular signalling. Including it in a mitochondrial peptide guide might seem odd until you look at how mitochondrial research is actually designed. Many studies that discuss mitochondrial peptides also measure NAD+/NADH ratios, sirtuin activity, PARP activity, CD38-related metabolism, mitochondrial respiration, and salvage-pathway dynamics. NAD+ is often the biochemical background against which peptide effects are interpreted.

The dedicated NAD+ Canada guide explains the cofactor in more detail. Here, the key point is that NAD+ answers a different question than SS-31, MOTS-c, or Humanin. NAD+ research asks about redox state, enzymatic cofactor availability, and signalling systems that consume NAD+. SS-31 asks about mitochondrial membrane organisation. MOTS-c and Humanin ask about peptide signalling derived from mitochondrial genomes. These questions can overlap in a complex study, but they should not be treated as the same intervention.

A protocol that combines NAD+ research material with SS-31 or MOTS-c should pre-specify the causal model. Is NAD+ being used as a comparator, a cofactor rescue, a parallel anti-aging axis, or a mechanistic readout? Without that clarity, a multi-compound mitochondrial stack becomes difficult to interpret. If respiration improves, was it due to membrane cardiolipin effects, altered redox availability, transcriptional changes, or a non-specific cell-health effect? The more compounds in the system, the more disciplined the endpoint design must be.

Supplier standards for NAD+ differ from peptide standards because the chemistry differs. Researchers should still demand lot-matched identity and purity testing, but the relevant analytics may include HPLC, water content, degradation products, and storage stability rather than peptide-sequence confirmation. NAD+ is susceptible to degradation under heat, moisture, and pH stress. Shipping and storage conditions matter, especially in Canadian winter and summer temperature extremes.

Evidence quality: mitochondrial mechanism is not clinical proof#

Mitochondrial dysfunction is a recognised hallmark of ageing biology, but that phrase does not convert preclinical data into clinical outcomes. A compound can improve mitochondrial respiration in a dish and fail to improve tissue function. It can improve a disease-specific biomarker and have no relevance to healthy ageing. It can reduce reactive oxygen species in one model while producing no measurable benefit in another. Serious mitochondrial research starts by accepting that mitochondria are central but not solitary.

SS-31 illustrates the point well. The cardiolipin mechanism is strong, and the Barth syndrome approval is important, yet studies in other conditions have been mixed. Some models show improved mitochondrial function without corresponding organ-level recovery. That is not a failure of the mechanism; it is a reminder that tissue damage, fibrosis, inflammation, vascular changes, genetics, and disease stage can dominate the phenotype.

MOTS-c and Humanin have a different evidence challenge. They are biologically compelling, but much of the work remains preclinical or early translational. Their mechanisms involve signalling networks rather than a single structural target. That makes them attractive for systems-biology research but difficult for simple product claims. A vendor that describes MOTS-c as a guaranteed fat-loss or anti-aging peptide is skipping many inferential steps.

NAD+ has the broadest popular awareness and perhaps the highest risk of category confusion. Raising or measuring NAD+ is not the same as improving mitochondrial function in a clinically meaningful way. NAD+ metabolism intersects with sirtuins, PARPs, CD38, immune activation, DNA repair, and circadian biology. A change in NAD+ availability can be mechanistically useful, but the downstream effect depends on cell type, stress condition, age, tissue, and disease context.

The conservative Canadian interpretation is therefore simple: mitochondrial mechanism creates a hypothesis, not a health claim. Researchers should use mitochondrial endpoints to test that hypothesis, and suppliers should avoid language that implies disease treatment, longevity benefit, or personal-use outcomes.

Designing a mitochondrial peptide study without overclaiming#

A strong mitochondrial peptide study starts with the defect being modelled. "Mitochondrial support" is not a research question. "Does SS-31 preserve cardiolipin-dependent respiration in oxidatively stressed cardiomyocytes?" is a research question. "Does MOTS-c alter AMPK phosphorylation and glucose uptake in aged skeletal-muscle cells?" is a research question. "Does Humanin reduce apoptosis markers after amyloid-beta exposure in a neuronal cell model?" is a research question. "Does NAD+ availability change the NAD+/NADH ratio and sirtuin-linked transcription under metabolic stress?" is a research question.

The second step is selecting endpoints that sit close to the proposed mechanism. For SS-31, that may include cardiolipin species, cristae morphology, oxygen consumption, membrane potential, cytochrome c peroxidase activity, and ATP production. For MOTS-c, it may include AMPK phosphorylation, glucose uptake, gene-expression profiling, mitochondrial biogenesis markers, and exercise-like adaptation markers. For Humanin, apoptosis markers, receptor-pathway readouts, stress-survival assays, and inflammatory markers may be more relevant. For NAD+, redox ratio, NAD+ consumption enzymes, salvage-pathway intermediates, and mitochondrial respiration can all be appropriate.

The third step is separating analytical from biological failure. If a peptide study produces no effect, the result might mean the mechanism is absent in that model. It might also mean the peptide degraded, adsorbed to plastic, was misidentified, formed aggregates, lost activity during shipping, or was stored incorrectly after reconstitution. Mitochondrial studies are especially sensitive because endpoints such as respiration can be affected by cell density, passage number, media composition, oxygen tension, assay temperature, and substrate selection.

The fourth step is resisting stack inflation. Mitochondrial dysfunction tempts researchers to combine SS-31, MOTS-c, NAD+, antioxidants, exercise mimetics, and senolytics in one protocol. That may look comprehensive, but it often destroys interpretability. If a combination is necessary, use a factorial design or a phased design that can distinguish individual and interaction effects. Otherwise, the protocol produces a positive or negative signal without explaining why.

Quality-control standards for Canadian sourcing#

Mitochondrial peptides demand ordinary peptide quality control plus mechanism-specific attention. At minimum, Canadian researchers should look for:

• Lot-matched certificate of analysis with the same batch number as the vial.
• HPLC purity with chromatogram context, not only a marketing percentage.
• Mass-spectrometry confirmation of expected molecular weight.
• Sequence identity and modification confirmation for peptides such as SS-31.
• Fill amount and whether the value reflects gross lyophilised mass or active peptide content.
• Storage conditions, shipping expectations, test date, and retest or expiry logic.
• Clear research-use-only positioning without disease-treatment or personal-use claims.
• Documentation of endotoxin or microbial expectations where the model requires it.

The Canadian research-peptide buyer's guide covers these standards more broadly. For mitochondrial work, there are additional considerations. SS-31's dimethyltyrosine and D-Arg configuration should be identified. MOTS-c and Humanin should be checked for truncation and degradation. NAD+ should be checked for moisture and degradation products rather than peptide sequence. Reconstituted materials should be handled with strict temperature and time controls because mitochondrial assays can be sensitive to small changes in active concentration.

Canadian shipping conditions are not trivial. A package may experience sub-zero exposure in winter or heat in summer. Lyophilised peptides are generally more stable than reconstituted solutions, but freeze-thaw cycles, moisture ingress, and prolonged heat can still matter. A serious lab should record arrival condition, storage temperature, reconstitution date, freeze-thaw events, and assay timing. Those details are not paperwork; they are potential explanations for discordant mitochondrial results.

ProductLink attribution and event-data instrumentation on this page#

Northern Compound uses ProductLink components for live product references rather than raw Lynx URLs. In this article, SS-31, MOTS-c, and NAD+ appear through ProductLink so each outbound product reference includes utm_source=northerncompound, utm_medium=blog, utm_campaign=product_link, utm_content=mitochondrial-peptides-canada-guide, and utm_term for the relevant slug. ProductLink also adds click-event attributes such as data-event="nc_product_link_click", data-product-slug, and data-post-slug.

That instrumentation matters because this site is an editorial funnel, not a generic catalogue. The goal is to measure whether cautious, research-use-only education sends qualified readers to Lynx without weakening compliance language or hiding the commercial relationship. The article deliberately does not link Humanin as a product because that slug is confirmed unavailable. It also does not include raw Lynx product URLs, inline CTABlock components, or duplicate disclaimers; the blog page template renders the global disclosure and CTA once.

Where this guide fits in the archive#

This article sits between several existing Northern Compound resources. The SS-31 guide is the best next read for cardiolipin and elamipretide. The MOTS-c guide is better for metabolic and exercise-adaptation questions. The Humanin guide covers the cytoprotective mitochondrial-derived peptide literature, while the NAD+ guide explains redox cofactor biology. The Epitalon vs SS-31 comparison is useful when the decision is telomere biology versus mitochondrial membrane pharmacology.

The gap this page fills is the umbrella query: "mitochondrial peptides Canada." That search does not necessarily mean the reader knows whether they need SS-31, MOTS-c, Humanin, or NAD+. A good archive page should slow the decision down and define the research layers before the reader reaches a product link. That is better SEO, better compliance, and better conversion quality.

Common interpretation errors#

The first error is treating every mitochondrial compound as an ATP booster. ATP is one output of mitochondrial function, but not the only one. Mitochondria regulate apoptosis, calcium, redox signalling, innate immunity, steroidogenesis, thermogenesis, and metabolite production. A compound can influence one of those systems without improving ATP production.

The second error is assuming mitochondrial origin equals mitochondrial targeting. MOTS-c and Humanin are mitochondrial-derived peptides, but that does not mean they physically localise to cardiolipin or repair cristae. SS-31 is the better example of a mitochondria-targeted membrane peptide. Origin and destination are different concepts.

The third error is assuming a rare-disease approval validates a general longevity use. Elamipretide's Barth syndrome milestone is scientifically important, but it is indication-specific and formulation-specific. It should strengthen mechanistic interest, not encourage off-label personal-use claims for RUO material.

The fourth error is assuming that NAD+ is interchangeable with mitochondrial peptides. NAD+ belongs in mitochondrial research because redox metabolism is central, but it is not a peptide and does not answer the same mechanistic questions.

The fifth error is ignoring availability and link integrity. Humanin can be scientifically relevant while unavailable from a given store. Northern Compound separates the literature discussion from live product linking so readers are not sent to dead pages or given inaccurate sourcing signals.

FAQ#

References and further reading#

• Sabbah, H. N. et al. Review of elamipretide/SS-31 mitochondrial membrane pharmacology and cardiolipin-related mechanisms. PubMed.
• Lee, C. et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. PubMed.
• Kim, S. J. et al. Mitochondrial-derived peptides as novel regulators of metabolism. PubMed.
• Muzumdar, R. H. et al. Humanin and metabolic/cytoprotective signalling in stress-response models. PubMed.
• Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm your health. Health Canada advisory.

Bottom line#

Mitochondrial peptide research is strongest when it is specific. SS-31 belongs in cardiolipin and inner-membrane studies. MOTS-c belongs in mitochondrial-derived metabolic signalling. Humanin belongs in cytoprotection and stress-response research, but should not be linked as a live product when availability is confirmed dead. NAD+ belongs beside the group as a redox and cofactor comparator, not as a peptide substitute.

For Canadian researchers, the practical standard is the same across the category: define the mitochondrial layer, choose endpoints that match the mechanism, verify batch-level documentation, preserve cold-chain discipline, and keep all claims within a research-use-only frame. Anything broader turns a useful mitochondrial research guide into marketing noise.